Investigational drug · Phase 2
IMGN632
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "IMGN632"
First trial start
2018
Jan 2, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMGN632", any sponsor or status.
Conditions studied
As listed on its trial records.
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Myeloproliferative Neoplasm
- Acute Myeloid Leukemia
Approved drugs for the same conditions: Acute myeloid leukemia · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "IMGN632" as an intervention, largest first.
- IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04086264 · 218 participants · Start Nov 6, 2019 · Primary completion Feb 2027
Drug: Azacitidine; IMGN632 and 1 more · For: Acute Myeloid Leukemia
Sites: Duarte, California; Orange, California; Tampa, Florida · 29 sites in all
AbbVieAbbVie (ABBV)
NCT03386513 · 179 participants · Start Jan 2, 2018 · Primary completion Oct 2, 2024
Drug: IMGN632 · For: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 18 sites in all
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruiting
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06034470 · 30 participants · Start Dec 18, 2023 · Primary completion May 31, 2026
Drug: Cytarabine; Fludarabine and 3 more · For: Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome and 2 more
Sites: Seattle, Washington
Children's Oncology GroupResearch network
NCT05320380 · 0 participants · Start Aug 1, 2023 · Primary completion Sep 1, 2023
Drug: Anti-CD123 ADC IMGN632; Cytarabine and 5 more · For: Recurrent Acute Myeloid Leukemia; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Mixed Phenotype Acute Leukemia and 5 more
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
Cole FM, Laszlo GS, Lunn-Halbert MC, et al. · Leukemia 2025
- Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting.
Dhakal P, Sy M, Sutamtewagul G, et al. · J Immunother Precis Oncol 2024
- Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG, Montesinos P, DeAngelo DJ, et al. · Lancet Oncol 2024
- Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S, Galati D, De Filippi R, et al. · Int J Mol Sci 2024
- [Clinicopathological diagnosis of blastic plasmacytoid dendritic cell neoplasm: Report of three cases].
Rienda I, Martínez-Cózar V, Torres-Navarro I, et al. · Rev Esp Patol 2024
- Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A, Sweet K · J Natl Compr Canc Netw 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.